Chronic hepatitis C in HIV-coinfected patients: Feasibility and efficacy of interferon-α2b and ribavirin combination therapy [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 3, 2001, Pages 299-300

  Nasti, Guglielmo ^a   Di Gennaro, Giampiero ^a   Rizzardini, Giuliano ^b   Cadorin, Lucia ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANEMIA; CHRONIC ACTIVE HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LETTER; LIVER TOXICITY; MALE; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0035281360     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200103010-00016     Document Type: Letter

References (4)

1. Management of chronic hepatitis in HIV-infected patients
2. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
3. Efficacy and safety of combination therapy with interferon-α 2b and ribavirin for chronic hepatitis C in HIV-infected patients